Full-Time

Associate Director

Posted on 11/23/2025

Sarepta

Sarepta

1,001-5,000 employees

Develops gene therapies for rare diseases

Compensation Overview

$168k - $210k/yr

San Francisco, CA, USA + 1 more

More locations: Portland, OR, USA

Hybrid

Category
Business & Strategy (2)
,
Required Skills
JIRA
Requirements
  • Bachelor's degree (BA/BS) from an accredited school required, MBA preferred
  • 10 years of relevant experience with 5-8 years of field experience in biotech industry, reimbursement experience preferred
  • Key account management, sales management, account management and/or rare disease product launch experience in Neuromuscular, Pediatric Neurology, Oncology, or other specialty experience in biotech, including launch experience in rare disease space preferred
  • Basic knowledge and understanding of compliance with HIPAA and OIG guidance in the rare disease space
  • Hospital finance, claims processing, and/or billing/coding experience preferred
  • Ability to learn and eventually navigate the complex payer landscape including a deep understanding of access and payer approval process for prescribed Sarepta therapies with a deep understanding of payer policies for our products
  • Primary understanding of the prior authorization process, denial management, product acquisition via the specialty pharmacy, buy-and-bill, IV infusion coding and reimbursement within multiple sites of care
  • Understands both the buy-and-bill process and specialty pharmacy networks, managed care, benefit design, government payers and their impact on product access with excellent working knowledge of evolving market access and reimbursement landscape
  • Knowledge of infused-biologic therapies for chronic, rare diseases
  • Self-driven individual looking to excel in a high pace Market Access/Reimbursement environment who has excellent time management and organizational skills
  • Capability to adapt to changing business needs and conditions while working with a variety of situations, individuals, groups and varying customer needs; including ability to utilize technologies to work in a virtual setting when travel is restricted
  • Ability to listen to others and communicate cross-functionally in an effective manner to overcome access obstacles
  • Demonstrates willingness to collaborate with internal colleagues and the ability to influence others
  • Valid driver’s license and in good standing
  • Ability to travel up to approximately 60% when living within the assigned geographic region
Responsibilities
  • Educate healthcare professionals and sites of care on prior authorization/reauthorization process, assist with the navigation of the denial/appeal process and with product procurement through buy-and-bill and limited distribution network; understand miscellaneous product codes and administration codes as well as the introduction of specific J-codes to assist with claims submissions
  • Expand knowledge of reimbursement landscape eventually being able to identify barriers hindering patient access and educate healthcare professionals of this process for prescribed Sarepta therapies
  • Build expertise to analyze, monitor and triage situations which may adversely impact patient access to therapy and assist in resolving distribution access challenges
  • Partner with SareptAssist Case Manager to navigate the Specialty Pharmacy communication and utilize critical thinking to strategically identify/prevent access and reimbursement issues where possible
  • Responsible for understanding and upholding Sarepta’s Legal and Compliance guidance at a customer and field leadership level related to access, cost and reimbursement issues
  • Build relationships through consistent communication and collaboration with internal and external stakeholders while delivering valuable reimbursement support and information to help providers facilitate the patient access journey for their Duchenne muscular dystrophy families for approved Sarepta therapies
  • Identify and profile sites of care and key stakeholders within given territory and initiate discussions with key stakeholders and evaluate operational effectiveness at each site
  • Utilize unconventional thinking to validate and gain a deep understanding of site capabilities, identify gaps and develop gap resolution plans; determine the processes in place and possible actions focused on site capacity, equipment, and additional resource needs
  • Engage with C-suite leadership, administration, revenue cycle management, finance, managed care team, contracting, pharmacy, PA departments and care team and deliver presentations on FDA approved label for Sarepta products, product procurement options, and pricing information to minimize barriers to patient access
  • Support healthcare professional champion through formulary inclusion/decision process and monitor Pharmacy and Therapeutic Committee timelines to confirm site readiness
  • Facilitate ongoing communication with sites sharing best practices through constant dialogue from both a clinical and commercial expertise focusing on retraining needs and challenge resolution
  • Exhibits willingness to make informed decisions working efficiently and effectively ensuring timely access to Sarepta products for identified patients
Desired Qualifications
  • MBA preferred
  • Launch experience in rare disease space preferred
  • Key account management, sales management, account management and/or rare disease product launch experience in Neuromuscular, Pediatric Neurology, Oncology, or other specialty experience in biotech, including launch experience in rare disease space preferred
  • None

Sarepta Therapeutics focuses on developing precision genetic medicines to treat rare diseases. It specializes in Duchenne muscular dystrophy (DMD) and is advancing gene therapies for limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth disease, MPS IIIA, and other CNS disorders. The company conducts research and development, carries therapies through clinical trials, and seeks regulatory approvals to bring treatments to patients, earning revenue from approved therapies and strategic partnerships. Its goal is to speed up drug development from lab research to patient treatment and to build the world’s largest gene therapy manufacturing capacity to meet global demand.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hits $731 million, beating estimates by 56%.
  • $700 million notes refinanced to 2030, bolstering $954 million cash.
  • $600 million credit facility funds ELEVIDYS reset and pipeline advances.

What critics are saying

  • FDA denies AMONDYS 45, VYONDYS 53 conversions, slashing $228 million revenue.
  • Elevidys triggers permanent FDA restrictions after liver injuries, zeroing sales.
  • CEO Ingram retires end-2026, sparking talent exodus and pipeline delays.

What makes Sarepta unique

  • Sarepta leads DMD with PMO therapies generating $229 million in Q1 2026.
  • ELEVIDYS delivers 70-73% slower DMD progression in EMBARK Phase III trial.
  • Pipeline expands to DM1, FSHD siRNA and Huntington's trials by H1 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Company News

Yahoo Finance
Mar 23rd, 2026
Sarepta seeks FDA approval conversion for AMONDYS 45 and VYONDYS 53 using ESSENCE Phase 3 data

Sarepta Therapeutics has received FDA agreement to file supplemental applications by end of April seeking conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approvals, using data from the ESSENCE Phase 3 study and real-world evidence in Duchenne muscular dystrophy. The regulatory conversion could validate Sarepta's exon-skipping platform and strengthen its DMD franchise durability. However, the company faces ongoing safety concerns around its gene therapy ELEVIDYS. Sarepta is enrolling non-ambulant patients to test an enhanced immunosuppression regimen, with primary endpoints focused on acute liver injury incidence. The company's narrative projects $1.4 billion revenue and $171.6 million earnings by 2028, implying 17% annual revenue decline. Most optimistic analysts forecast $713.6 million earnings on $1.9 billion revenue by 2028.

Yahoo Finance
Mar 3rd, 2026
Bavarian Nordic CEO steps down amid pharma leadership shake-up

Bavarian Nordic has announced that CEO Paul Chaplin will step down after 11 years leading the Danish vaccine specialist, marking the latest executive change in pharmaceuticals this year. Chaplin, who joined in 2014, is leaving for personal reasons as his family relocates to Australia. He will remain until year-end or until a successor is found. The move follows recent departures elsewhere. Sarepta's Doug Ingram announced his retirement last month after a decade as CEO, citing family health concerns. Sanofi revealed in February it would not renew Paul Hudson's contract after six years, with share prices falling over 20% since February 2025. Belén Garijo, currently CEO of Merck KGaA, will take over at Sanofi from 29 April.

Yahoo Finance
Mar 1st, 2026
Wells Fargo cuts Sarepta Therapeutics price target to $38 from $45 after GTx launch delays

Wells Fargo has cut its price target on Sarepta Therapeutics to $38 from $45, maintaining an Overweight rating. The firm adjusted its ELEVIDYS projections, noting the gene therapy launch reset following safety events may take longer than anticipated based on 2026 guidance. However, Wells Fargo expects positive results from the company's siRNA readout. Separately, Baird reduced its price target to $20 from $22 with a Neutral rating following Sarepta's fiscal 2025 results. The company reported full-year net product revenues of $1.864 billion, comprising $965.6 million from PMO products and $898.7 million from ELEVIDYS. Sarepta Therapeutics develops RNA-targeted therapeutics and gene therapy for rare diseases, with several approved treatments for Duchenne muscular dystrophy.

Yahoo Finance
Feb 26th, 2026
Sarepta Therapeutics CEO Ingram to retire after tumultuous year for gene therapy Elevidys

Sarepta Therapeutics CEO Douglas Ingram will retire by the end of 2026 or upon appointment of his successor, the company announced in a regulatory filing. The firm has begun searching for his replacement. Ingram's departure follows a turbulent 2025 for the biotech company. Its gene therapy Elevidys, used to treat a muscle disorder, was linked to two patient deaths, prompting the FDA to request voluntary shipment halts. The company cut 500 jobs and halted development of several gene therapies. Elevidys carries the FDA's most serious safety warning and requires stringent monitoring. Despite the setbacks, Ingram said on Wednesday the therapy is on a potential pathway for expanded use. Sarepta's shares fell 82% last year and were down 4% in after-market trading. Ingram has led the company since 2017.

Yahoo Finance
Feb 26th, 2026
Sarepta posts $1.86B revenue, guides $1.2B–$1.4B for 2026 as CEO plans retirement

Sarepta Therapeutics reported 2025 net product revenue of $1.86 billion, comprising $966 million from its PMO franchise and $899 million from ELEVIDYS. The company guided 2026 approved-therapy revenue between $1.2 billion and $1.4 billion, whilst ending 2025 with $954 million in cash. Management described 2026 as a commercial "critical reset" for ELEVIDYS following two fatal events in 2025. Clinically, EMBARK three-year data showed a statistically significant 4.39-point NSAA benefit and approximately 70–73% slowing on key functional measures. Proof-of-concept readouts for DM1 and FSHD siRNA programmes are expected by end-Q1, with a Huntington's trial to begin in H1 2026. CEO Doug Ingram announced plans to retire around end-2026, with the board conducting a comprehensive successor search.

INACTIVE